1350890-84-4Relevant academic research and scientific papers
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity
Sheldrake, Helen M.,Travica, Sandra,Johansson, Inger,Loadman, Paul M.,Sutherland, Mark,Elsalem, Lina,Illingworth, Nicola,Cresswell, Alexander J.,Reuillon, Tristan,Shnyder, Steven D.,Mkrtchian, Souren,Searcey, Mark,Ingelman-Sundberg, Magnus,Patterson, Laurence H.,Pors, Klaus
, p. 6273 - 6277 (2013/09/02)
A library of duocarmycin bioprecursors based on the CPI and CBI scaffolds was synthesized and used to probe selective activation by cells expressing CYP1A1 and 2W1, CYPs known to be expressed in high frequency in some tumors. Several CPI-based compounds w
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity
Pors, Klaus,Loadman, Paul M.,Shnyder, Steven D.,Sutherland, Mark,Sheldrake, Helen M.,Guino, Meritxell,Kiakos, Konstantinos,Hartley, John A.,Searcey, Mark,Patterson, Laurence H.
, p. 12062 - 12064 (2011/12/14)
The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the
